These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21995102)

  • 21. Aldosterone receptor antagonists: effective but often forgotten.
    Maron BA; Leopold JA
    Circulation; 2010 Feb; 121(7):934-9. PubMed ID: 20177008
    [No Abstract]   [Full Text] [Related]  

  • 22. Eplerenone in mild heart failure.
    Gus M; Fuchs FD
    N Engl J Med; 2011 Apr; 364(14):1370-1; author reply 1372. PubMed ID: 21470019
    [No Abstract]   [Full Text] [Related]  

  • 23. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 24. Eplerenone in patients with left ventricular dysfunction.
    Blaustein DA; Schwenk MH
    N Engl J Med; 2003 Jul; 349(1):88-9; author reply 88-9.. PubMed ID: 12846224
    [No Abstract]   [Full Text] [Related]  

  • 25. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
    Aaronson K
    Health News; 2003 May; 9(5):4. PubMed ID: 12739453
    [No Abstract]   [Full Text] [Related]  

  • 26. Mineralocorticoid receptor blockade in the protection of target organ damage.
    Mulatero P; Milan A; Williams TA; Veglio F
    Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):75-91. PubMed ID: 16529552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficient improvement of prognosis after myocardial infarct? Additional aldosterone inhibition is required].
    MMW Fortschr Med; 2005 Dec; 147(48):66-7. PubMed ID: 16392155
    [No Abstract]   [Full Text] [Related]  

  • 28. The evolution of aldosterone antagonists.
    Garthwaite SM; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):27-31. PubMed ID: 15134797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Yamamoto T
    Nihon Rinsho; 2007 May; 65 Suppl 5():102-6. PubMed ID: 17571373
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
    [No Abstract]   [Full Text] [Related]  

  • 32. Aldosterone antagonism and myocardial infarction: from animals to man and back.
    Solomon SD; Pfeffer MA
    J Am Coll Cardiol; 2003 Nov; 42(9):1674-6. PubMed ID: 14607458
    [No Abstract]   [Full Text] [Related]  

  • 33. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P; Ménard J; Fay R; Gustafsson F; Pitt B; Zannad F
    J Am Coll Cardiol; 2011 Nov; 58(19):1958-66. PubMed ID: 22032706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacology profile and clinical findings of Selara Tablets (eplerenone)].
    Nomura S; Tabira J; Hayashi T; Hamada Y
    Nihon Yakurigaku Zasshi; 2008 Oct; 132(4):227-35. PubMed ID: 18854625
    [No Abstract]   [Full Text] [Related]  

  • 35. [The use of aldosterone antagonists in the cardiovascular diseases].
    Trzaska E; Gumułka W; Makulska-Nowak HE
    Kardiol Pol; 2009 Jun; 67(6):667-71. PubMed ID: 19618325
    [No Abstract]   [Full Text] [Related]  

  • 36. Mineralocorticoid receptor antagonists and endothelial function.
    Maron BA; Leopold JA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
    Urabe A; Izumi T; Abe Y; Taniguchi I; Mochizuki S
    Hypertens Res; 2006 Aug; 29(8):627-34. PubMed ID: 17137219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
    Sato A
    Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.